REC N Stock Overview

Researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. More details

REC N fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	4/6

Rewards

Earnings are forecast to grow 12.12% per year

Earnings grew by 7.5% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Dividend of 2.47% is not well covered by free cash flows

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Recordati Industria Chimica e Farmaceutica S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Recordati Industria Chimica e Farmaceutica
Historical stock prices
Current Share Price	€1,188.76
52 Week High	€1,188.76
52 Week Low	€1,188.76
Beta	0.53
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	REC N	MX Pharmaceuticals	MX Market
7D	0%	-2.4%	-0.01%
1Y	n/a	-7.5%	-0.09%

Return vs Industry: Insufficient data to determine how REC N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how REC N performed against the MX Market.

Price Volatility

Is REC N's price volatile compared to industry and market?
REC N volatility
REC N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in MX Market	8.2%
10% least volatile stocks in MX Market	2.7%

Stable Share Price: REC N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine REC N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1926	4,539	Rob Koremans	recordati.com

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma.

Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary

How do Recordati Industria Chimica e Farmaceutica's earnings and revenue compare to its market cap?
REC N fundamental statistics
Market cap	Mex$231.23b
Earnings (TTM)	Mex$9.10b
Revenue (TTM)	Mex$52.53b

25.4x

P/E Ratio

4.4x

P/S Ratio

Is REC N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REC N income statement (TTM)
Revenue	€2.41b
Cost of Revenue	€732.70m
Gross Profit	€1.68b
Other Expenses	€1.26b
Earnings	€417.95m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 29, 2025

Earnings per share (EPS)	2.03
Gross Margin	69.64%
Net Profit Margin	17.32%
Debt/Equity Ratio	117.2%

How did REC N perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

63%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/19 22:13
End of Day Share Price	2025/02/19 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 26 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Paola Saglietti	Banca Akros S.p.A. (ESN)
Charles Pitman	Barclays
Nicolas Guyon-Gellin	BNP Paribas Exane

Recordati Industria Chimica e Farmaceutica BMV:REC N Stock Report